Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The osteosarcoma marketed and pipeline drugs assessment report provides a data-driven overview of the current and future competitive landscape in osteosarcoma therapeutics. Osteosarcoma is the most common primary pediatric bone malignancy, derived from primitive bone-forming mesenchymal cells, and is characterized by extensive and heterogeneous genetic complexity.
Osteosarcoma can be classified into various subtypes according to the degree of differentiation, location within the bone, and histological variation. Osteosarcoma can also be subdivided into primary and secondary forms. Primary tumors usually occur in the metaphysis of long bones around the knee. Children and adolescents account for the vast majority of those affected by this condition. Secondary tumors occur in higher incidence in flat bones such as the pelvis. It has a wider distribution due to the varied nature of the patients’ underlying predisposing conditions. Secondary tumors almost always occur in the adult population.
Osteosarcomas frequently occur near the metaphysis of the long bones of the appendicular skeleton. The most common locations include the femur, the tibia, and the humerus. Other potential sites include the skull or jaw and the pelvis. The prognosis of osteosarcoma depends on various factors such as age, gender, biomarker levels, tumor location, tumor burden, pathological fracture, and body mass index, among others.
What are the key regions in the osteosarcoma drugs market?
The key regions in the osteosarcoma drugs market are the US, Europe, and Asia-Pacific. The US has the highest number of trials in phase II, followed by Asia-Pacific and then Europe.
Which are the major countries in the osteosarcoma drugs market?
The major countries in the osteosarcoma drugs market are France, the US, China, Canada, the UK, Netherlands, Australia, Denmark, Belgium, and New Zealand. The US has the highest number of completed trials among the other top countries.
Osteosarcoma drugs market, by major countries
For more country insights, download a free sample
Which are the key drugs in the osteosarcoma drugs market?
The key drugs in the osteosarcoma drugs market include doxorubicin hydrochloride, ifosfamide, cisplatin, leucovorin calcium, levoleucovorin calcium, methotrexate, mifamurtide, and vincristine sulfate.
Osteosarcoma drugs market, by key drugs
For more drug insights, download a free sample
What are the key phases in the osteosarcoma drugs market?
The key phases in the osteosarcoma drugs market include discovery, pre-clinical, IND/CTA filed, phase I, phase II, and phase III. Among them phase II contains majority of the pipeline.
Osteosarcoma drugs market, by key phases
For more phase insights, download a free sample
Who are the key sponsors in the osteosarcoma drugs market?
The key sponsors in the osteosarcoma drugs market include Novartis, Celgene, Cellectar Biosciences, Eisai, and Isofol Medical. Novartis is the top sponsor in osteosarcoma clinical research with four clinical trials. After Novartis, the most active sponsors of osteosarcoma clinical trials are Celgene, Cellectar Biosciences, Eisai, and Isofol Medical.
Osteosarcoma drugs market, by key sponsors
To know about more key sponsors, download a free sample
Market report scope
Key regions | The US, Europe, and Asia-Pacific |
Major countries | France, the US, China, Canada, the UK, Netherlands, Australia, Denmark, Belgium, and New Zealand |
Key phases | Discovery, Pre-Clinical, IND/CTA Filed, Phase I, Phase II, and Phase III |
Key drugs | Doxorubicin Hydrochloride, Ifosfamide, Cisplatin, Leucovorin Calcium, Levoleucovorin Calcium, Methotrexate, Mifamurtide, and Vincristine Sulfate |
Key sponsors | Novartis, Celgene, Cellectar Biosciences, Eisai, and Isofol Medical |
Scope
- GlobalData’s Osteosarcoma marketed and pipeline drugs assessment, clinical trials, social media and competitive landscape, 2021-2027 combines data from the pharma intelligence center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the osteosarcoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global osteosarcoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key regions in the osteosarcoma drugs market?
The US, Europe, and Asia-Pacific are the key regions in the osteosarcoma drugs market.
-
Which are the major countries in the osteosarcoma drugs market?
France, the US, China, Canada, the UK, Netherlands, Australia, Denmark, Belgium, and New Zealand are the major countries in the osteosarcoma drugs market.
-
Which are the key drugs in the osteosarcoma drugs market?
Doxorubicin hydrochloride, ifosfamide, cisplatin, leucovorin calcium, levoleucovorin calcium, methotrexate, mifamurtide, and vincristine sulfate are the key drugs in the osteosarcoma drugs market.
-
What are the key phases in the osteosarcoma drugs market?
Discovery, pre-clinical, IND/CTA filed, phase I, phase II, and phase III are the key phases in the osteosarcoma drugs market.
-
Who are the key sponsors in the osteosarcoma drugs market?
Novartis, Celgene, Cellectar Biosciences, Eisai, and Isofol Medical are the key sponsors in the osteosarcoma drugs market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.